Analyzing CRISPR Therapeutics (NASDAQ:CRSP) and CureVac (NASDAQ:CVAC)

CRISPR Therapeutics (NASDAQ:CRSP) and CureVac (NASDAQ:CVAC) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, dividends, earnings, institutional ownership, risk and profitability.

Volatility and Risk

CRISPR Therapeutics has a beta of 1.76, meaning that its share price is 76% more volatile than the S&P 500. Comparatively, CureVac has a beta of 1.77, meaning that its share price is 77% more volatile than the S&P 500.

Institutional & Insider Ownership

69.2% of CRISPR Therapeutics shares are held by institutional investors. Comparatively, 17.3% of CureVac shares are held by institutional investors. 5.2% of CRISPR Therapeutics shares are held by company insiders. Comparatively, 2.1% of CureVac shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares CRISPR Therapeutics and CureVac’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CRISPR Therapeutics	-3,368.72%	-24.39%	-18.25%
CureVac	199.92%	-23.03%	-19.09%

Valuation and Earnings

This table compares CRISPR Therapeutics and CureVac”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CRISPR Therapeutics	$3.51 million	1,424.73	-$581.60 million	($4.76)	-10.87
CureVac	$70.74 million	14.78	$175.50 million	$0.72	6.47

CureVac has higher revenue and earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings for CRISPR Therapeutics and CureVac, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CRISPR Therapeutics	1	6	10	1	2.61
CureVac	1	0	0	0	1.00

CRISPR Therapeutics currently has a consensus price target of $68.06, suggesting a potential upside of 31.58%. Given CRISPR Therapeutics’ stronger consensus rating and higher possible upside, equities research analysts clearly believe CRISPR Therapeutics is more favorable than CureVac.

Summary

CRISPR Therapeutics beats CureVac on 8 of the 15 factors compared between the two stocks.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

About CureVac

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.